Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab

QR Code

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab

Bibliographic Details
Main Authors:	Chan, Arlene, McGregor, S.
Format:	Journal Article
Published:	Blackwell Publishing 2012
Online Access:	http://hdl.handle.net/20.500.11937/49060

Similar Items

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
by: Au, H., et al.
Published: (2013)

Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?
by: Chan, Arlene
Published: (2017)

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by: Chan, Arlene, et al.
Published: (2016)

Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: An analysis of 1655 patients
by: Chan, Arlene, et al.
Published: (2014)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah … [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018)

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by: Martin, M., et al.
Published: (2017)

Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy
by: Chan, Arlene, et al.
Published: (2013)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
by: Aung, Sanda, et al.
Published: (2014)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

HER2/neu-based peptide vaccination-pulsed with B-cell epitope induced efficient prophylactic and therapeutic antitumor activities in TUBO breast cancer mice model
by: Nordin, Muhammad Luqman, et al.
Published: (2021)

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

KM-NEU: an efficient hybrid approach for intrusion detection system
by: Lisehroodi, Mazyar Mohammadi, et al.
Published: (2014)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

The role of HER family signalling in breast cancer
by: Kuruppu, Anchala
Published: (2016)

Immune responses to Streptococcus agalactiae in red tilapia, Oreochromis spp. following vaccination with non-adjuvanted and adjuvanted vaccine incorporated feed pellets
by: Nawi, Mohd Firdaus
Published: (2011)

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines
by: Siti Norasikin Mohd Nafi,, et al.
Published: (2022)

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
by: Mackey, J., et al.
Published: (2016)

Expression of foxp3 tumour infiltrating lymphocytes in her2 positive breast cancer and their association with clinicopathological features
by: Hashim, Sobry
Published: (2023)

Factors associated with delayed time to adjuvant chemotherapy in stage III colon cancer
by: Chan, Arlene, et al.
Published: (2014)

Biological characterisation of HER2 amplified breast cancer
by: Barros, Fabrício Félix Tabuada
Published: (2013)

Multifunctional Poly(D,L-Lactide-co-Glycolide)/ Montmorillonite (PLGA/MMT) Nanoparticles Decorated by Trastuzumab for Targeted Chemotherapy of Breast Cancer
by: Ranganathan, Balu, et al.
Published: (2014)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

From von Neumann architecture and Atanasoff’s ABC to Neuromorphic Computation and Kasabov’s NeuCube. Part II: Applications
by: Doborjeh, Maryam, et al.
Published: (2018)

Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study)
by: Chan, Arlene, et al.
Published: (2017)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
by: Serra, V., et al.
Published: (2011)

Computational pathology and deciphering the complexity of HER2 expression in breast cancer
by: Atallah, Nehal Mohammed
Published: (2025)

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial
by: Eiermann, W., et al.
Published: (2011)

Depression, anxiety and streee in young adult breast cancer women undergoing adjuvant therapy in HUSM
by: Leng, Leong Yee
Published: (2011)

BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017)

Translational control of Human Epidermal Growth Factor Receptors, HER2 and HER4 in response to cellular stresses in breast cancer cells
by: Edwards, Arnelle
Published: (2023)

Pharmaceutical formulations as immunological adjuvants
by: O'Hagan, Derek Thomas
Published: (1987)

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
by: Cameron, David, et al.
Published: (2013)

Use of non anthracycline regimens in early stage breast cancer within Australia
by: De Boer, R., et al.
Published: (2011)

Her2 challenge contest: a detailed assessment of automated her2 scoring algorithms in whole slide images of breast cancer tissues
by: Qaiser, Talha, et al.
Published: (2018)